Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kevin J Harrington"'
Autor:
M. Denyer, Nicola E. Annels, Guy Simpson, Kevin J. Harrington, Richard G. Vile, Mehreen Arif, Hardev Pandha, Alan Melcher, Matthew C. Coffey
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 434-446 (2021)
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 434-446 (2021)
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely responsible for the lack
Autor:
Magnus T. Dillon, Martin McLaughlin, Anna Wilkins, Kevin J. Harrington, Malin Pedersen, Alan Melcher, Emmanuel C Patin
Publikováno v:
Nature Reviews Cancer. 20:203-217
The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic and acquired resistance
Publikováno v:
Nature Immunology. 21:120-134
Therapeutic irradiation of the tumor microenvironment causes differential activation of pro-survival and pro-death pathways in malignant, stromal, endothelial and immune cells, hence causing a profound cellular and biological reconfiguration via mult
Autor:
Kate Newbold, Shreerang Bhide, Alan Melcher, Amy Trinh, KH Wong, Pablo Nenclares, Lucinda Gunn, Heba Soliman, Mateo Bover, Kevin J. Harrington, Christopher M. Nutting, Isla Leslie, Derfel Ap Dafydd
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundPrevious studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with
Autor:
Jennifer Kingston, Anna Wilkins, Anguraj Sadanandam, Hannah Bye, David Mansfield, Jessica A. Downs, Elisa Fontana, A Noshirwani, Fiona Errington-Mais, Yatish Patil, Magnus T. Dillon, Katharina von Loga, Paul Carter, Kevin J. Harrington, Gift Nyamundanda, Daniel Bottomley, David Sebag-Montefiore, Sandra Demaria, Nicholas P. West, Chanthirika Ragulan, E Tinkler-Hundal, Alan Melcher
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundRectal cancers show a highly varied response to neoadjuvant radiotherapy/chemoradiation (RT/CRT) and the impact of the tumor immune microenvironment on this response is poorly understood. Current clinical tumor regression grading systems at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052136d6546eada06fa12d3ecaa8e106
https://eprints.whiterose.ac.uk/170165/30/e001717.full.pdf
https://eprints.whiterose.ac.uk/170165/30/e001717.full.pdf
Autor:
Joan Kyula-Currie, Andrew J. Hayes, Radhika R. Patel, Khin Thway, Katharina F. Bergerhoff, James T. Paget, Victoria Roulstone, Martin McLaughlin, Henry G. Smith, Alan Melcher, Kevin J. Harrington, Aadil A. Khan, Magnus T. Dillon, David Mansfield
Publikováno v:
Clinical Cancer Research. 25:3443-3454
Purpose: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor monotherapy has shown little activity in sarcoma and there is great interest in identifying novel treatment combinations that
Publikováno v:
The Journal of Pathology. 247:606-614
Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell-autonomous mechanisms of cell death. Here, tumour cell death occurs when a threshold number of radiation-induced non-reparable double-stranded DNA breaks is e
Autor:
Victoria Roulstone, Patrycja Gazinska, Alan Melcher, Andrew J. Hayes, Gareth J. Inman, Gianmaria Liccardi, Kevin J. Harrington, Naomi Guppy, Emma Davies, Pascal Meier, Jasbani H.S. Dayal, Joan Kyula-Currie, Kunzah Jamal, Henry G. Smith, Tencho Tenev, Ioannis Roxanis
Publikováno v:
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 12, Iss 6, Pp n/a-n/a (2020)
EMBO Molecular Medicine, Vol 12, Iss 6, Pp n/a-n/a (2020)
Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti‐tumour immunity but not every form of death can elicit an immune response. Moreover, resis
Publikováno v:
Nature reviews. Drug discovery. 18(9)
In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently seen as a potential therapeutic option for patients with cancer who do not respond or fail to achieve durable responses following treatment with immune checkpoi
Autor:
Nicola E. Annels, Richard G. Vile, Mehreen Arif, M. Denyer, Darren R. Shafren, Izhar Bagwan, Carmen Ballesteros-Merino, Bernard A. Fox, Bronwyn Davies, Guy Simpson, Hardev Pandha, Gough G. Au, David Mansfield, Kevin J. Harrington, Mark Grose, Sarbjinder S Sandhu, Hugh Mostafid, Alan Melcher
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(19)
Purpose: The CANON [CAVATAK in NON–muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Patients and Methods: Fifteen patients enro